Results 151 to 160 of about 32,499 (205)

Cryptococcal Osteomyelitis in a Virally Suppressed Adolescent Living With HIV: A Case Report. [PDF]

Case Rep Infect Dis
Mandikiyana Chirimuta LA, Rambanapasi C, Musorowegomo D, Nyatanga G, Mapfumo A, Chikati EF.   +5 more
europepmc   +1 more source

Fisetin as an Antiviral Agent Targeting the RNA-Dependent RNA Polymerase of SARS-CoV-2: Computational Prediction and In Vitro Experimental Validation. [PDF]

Microorganisms
Hernández-Rodríguez X, Lira-Hernández FI, Reyes-Ruíz JM, Osuna-Ramos JF, Farfán-Morales CN, Calderón-Sandate DN, Castañeda-Delgado JE, León-Juárez M, Ángel RMD, Rivas-Santiago B, Noriega S, Cañedo-Figueroa DM, Montaño S, Santos-Mena AO, García-Herrera AC, De Jesús-González LA.   +15 more
europepmc   +1 more source

A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks. [PDF]

AIDS
Stephen ZR, Perazzolo S, Duan L, Eguchi M, Tian B, Klein K, Kinman L, Delle Fratte R, Adams Waldorf KM, Barton T, Melvin AJ, Ho RJY.   +11 more
europepmc   +1 more source

Prevalence of high-risk human papillomavirus genotypes and associated factors among HIV-infected women in a reproductive age group attending antiretroviral therapy in Nekemte town, Oromia, Ethiopia. [PDF]

PLoS One
Gebeyehu R, Gizaw S, Amensisa D, Bekele T, Merkeb B, Alemu F, Cewaka G.   +6 more
europepmc   +1 more source

Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial. [PDF]

Clin Infect Dis
Wyncoll J, Kamolrattana R, Archary M, Mujuru HA, Kekitiinwa AR, Violari A, Na-Rajsima S, Lugemwa A, Variava E, Cotton M, Kityo CM, Königs C, Behuhuma NO, Welch S, Saïdi Y, Marques L, Ahimbisibwe GM, Houlden L, Giaquinto C, Rojo P, Gibb DM, Puthanakit T, Turkova A, White E, Ford D, ODYSSEY Trial Team.   +25 more
europepmc   +1 more source

Central auditory tests reveal deficits in HIV treatment. [PDF]

Front Public Health
Kambhampaty AK, Niemczak CE, Hill RA, Howe CG, Leigh SM, Lichtenstein J, Roth RM, Adhikari M, Zhang L, Fellows AM, Magohe A, Palumbo P, Gui J, Massawe ER, Buckey JC.   +14 more
europepmc   +1 more source

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Lopinavir

Drugs, 2000
Lopinavir is a protease inhibitor with high specificity for HIV-1 protease. Ritonavir strongly inhibits lopinavir metabolism; coadministration of lopinavir and ritonavir in healthy volunteers increased the area under the lopinavir plasma concentration-time curve >100-fold.
M, Hurst, D, Faulds
  +5 more sources

Lopinavir/Ritonavir in Pregnancy

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
The Antiretroviral Pregnancy Registry was established in 1989 to collect data on birth defects after pregnancy exposures to antiretroviral therapy. Using Registry data, this study estimates the birth defect risk after pregnancy exposures to lopinavir/ritonavir.The analysis population includes all prospective lopinavir/ritonavir-exposed pregnancies ...
Susan S, Roberts, Marisol, Martinez, Deborah L, Covington, Richard A, Rode, Mary V, Pasley, William C, Woodward   +5 more
openaire   +2 more sources